<DOC>
	<DOCNO>NCT00249002</DOCNO>
	<brief_summary>This study design confirm safety propose dose schedule ABI-007 hemodialysis patient vascular access device failure , obtain preliminary data effectiveness treatment .</brief_summary>
	<brief_title>Use ABI-007 Prevention Vascular Access Graft Failure Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>This open-label , pilot , phase II study ass feasibility administer ABI-007 intravenously [ IV ] 3-5 minute patient hemodialysis graft dysfunction ( i.e. , either thrombose polytetrafluoroethylene ( PTFE ) graft , patent dysfunctional PTFE graft ) . Patients graft dysfunction successfully treat angioplasty start treatment angioplasty first dialysis graft follow intervention , receive 3 subsequent treatment ABI-007 35 mg/m^2 week 5 , 13 21 .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Thrombosed graft within past 7 day patent dysfunctional polytetrafluoroethylene ( PTFE ) graft ( identified mean ) stenosis great 50 % graftvein anastomosis within 8 centimeter graftvein anastomosis refer index lesion . Following angioplasty patient must residual stenosis le 20 % post angioplasty index lesion stenosis ; also index lesion must locate arm . PTFE graft require angioplasty must least 30 day old . Male nonpregnant nonlactating female , ≥ 18 year age . Patient guardian provide sign write informed consent administration ABI007 ( postangioplasty time first dialysis new graft ) use form approve local IRB/ethics committee investigative site . Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity . Use stent time current angioplasty previous time index lesion . No perforation time current angioplasty . Thrombosed graft 7 day . Patient follow blood count baseline : Absolute neutrophil count ( ANC ) &lt; 2.0*10^9/L ; platelet &lt; 100*10^9/L ; Hemoglobin ( Hgb ) &lt; 9 g/dL . Patient follow blood chemistry level baseline : Aspartate transaminase ( AST SGOT ) , alanine transaminase ( ALT SGPT ) &gt; 2.5x upper limit normal range ( ULN ) ; total bilirubin ≥ upper limit normal ( ULN ) ; Unable give inform consent , informed consent obtain legal guardian . Women pregnant woman child bear potential use adequate contraception . 2 procedure percutaneous surgical intervention PTFE graft within previous 90 day . Previous participation another study investigational drug device within past 30 day current enrollment clinical protocol investigational trial . Patient life expectancy le 6 month . Intended kidney transplant within 6 month enrollment study Any significant medical condition investigator opinion may interfere patient optimal participation study . Patient , investigator 's opinion , unlikely able complete study End Study ( EOS ) visit . Patient history allergy hypersensitivity study drug . Documented hypercoagulable state require anticoagulation ( protein S , protein C , antiphospholipid ; anticoagulation empiric basis graft thrombose contradiction ) . Patient human immunodeficiency virus ( HIV ) positive . Patient currently receive chemotherapy drug ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Vascular Access Graft Failure</keyword>
	<keyword>Venous Neointimal Hyperplasia ( VNH )</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>